Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China

OBJECTIVE: To assess the economic evaluation of margetuximab plus chemotherapy over trastuzumab plus chemotherapy for women with pretreated ERBB2-positive advanced breast cancer in the United States (US) and China. METHODS: Based on the SOPHIA trial, a three-state Markov model was developed to compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zhiyuan, Xu, Xin, Gao, Jie, Chen, Ling, Zhu, Qiuyan, Wang, Jinli, Yan, Xiaoyu, Chen, Bohua, Zhu, Yumei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500445/
https://www.ncbi.nlm.nih.gov/pubmed/36159262
http://dx.doi.org/10.3389/fpubh.2022.942767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500445/
https://www.ncbi.nlm.nih.gov/pubmed/36159262
http://dx.doi.org/10.3389/fpubh.2022.942767

Ejemplares similares